Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Pre-exposure prophylaxis Stories

2011-12-13 07:21:00

New educational program reminds parents to keep medication "Up and Away and Out of Sight" ATLANTA, Dec. 13, 2011 /PRNewswire-USNewswire/ -- Each year, one of every 150 two-year-olds visits an emergency department in the United States for an unintentional medication overdose, most often after finding and eating or drinking medicines without adult supervision. To inform parents and caregivers about safe medication storage and what to do in case of an emergency, CDC, the Consumer...

2011-12-08 10:25:06

New research from the University of North Carolina at Chapel Hill schools of medicine and pharmacy may help explain the failure of some recent clinical trials of prevention of HIV infection, compared to the success of others that used the same drugs. The study published online December 7, 2011 in the journal Science Translational Medicine, also suggests how to improve the chances for success, even before the research begins. These suggestions are reinforced in an editorial by several of...

2011-12-07 23:08:59

A new weapon has emerged to prevent HIV infection. Called pre-exposure prophylaxis, or PrEP, it is a strategy of providing medications to at-risk people before they are exposed to the virus. Having shown great promise in recent phase 3 clinical trials, PrEP may soon be rolled out for public use. Because PrEP is based on the same drugs used to treat HIV-infected individuals, the big public health fear is that the dual use of these drugs will lead to skyrocketing levels of drug resistance....

2011-11-28 17:23:02

VOICE, an HIV prevention trial that has been evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women — daily use of one of two different ARV tablets or of a vaginal gel — will be dropping the vaginal gel from the study. The decision to discontinue use of the gel, which contains the ARV tenofovir, comes after a routine review of study data concluded that tenofovir gel was not effective in preventing HIV in the women enrolled in...

2011-11-28 17:21:17

Product safe but no more effective than placebo A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational microbicide, was not effective among study participants. On Nov. 17, an independent data and safety monitoring board (DSMB) recommended that the Vaginal and Oral Interventions to Control the Epidemic (VOICE)...

2011-10-18 12:13:00

NEW YORK, Oct. 18, 2011 /PRNewswire-USNewswire/ -- Thirteen prominent U.S. HIV/AIDS organizations have issued an open letter to the U.S. Food and Drug Administration and Gilead Sciences calling for prompt regulatory review of pre-exposure prophylaxis (PrEP) for HIV prevention in gay and bisexual men and transgender women (men who have sex with men, or MSM). The letter urges FDA and Gilead to start the review process that could allow safe and appropriate approved PrEP use as a public health...

2011-09-28 19:41:49

VOICE will continue testing other ARV-based approaches: oral Truvada and tenofovir gel VOICE, an HIV prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women — daily use of one of two different ARV tablets or of a vaginal gel — will be dropping one of the oral tablets from the study. The decision to discontinue use of tenofovir tablets in VOICE comes after a routine review of study data concluded that the trial...

2011-09-28 19:39:18

Oral tenofovir discontinued in clinical trial A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective. An independent data and safety monitoring board (DSMB) recommended that the Vaginal and Oral Interventions to...

2011-09-28 13:36:00

Continued PrEP research more important than ever NEW YORK, Sept. 28, 2011 /PRNewswire-USNewswire/ -- The announcement today that one arm of a large-scale HIV prevention trial known as VOICE will stop early is disappointing, but must be seen in context, according to the global advocacy organization AVAC. "Of course we are disappointed to hear that the tenofovir pill arm of VOICE will not be able to answer the question of whether or not the drug prevents HIV infection in women in this...

2011-09-15 15:40:00

NEW YORK, Sept. 15, 2011 /PRNewswire-USNewswire/ -- Close to 100 openly HIV-positive gay and bisexual men from across the United States and around the world have signed a new letter (http://tinyurl.com/pozPrEPletter) calling for an open discussion, "based on facts rather than on fear or misinformation," of the challenges and opportunities presented by pre-exposure prophylaxis (PrEP) for HIV prevention in gay and bisexual men and transgender women. The new open letter is designed in part to...